Silence management enthusiastic ahead of catalysts, says H.C. Wainwright

H.C. Wainwright analyst Patrick Trucchio reiterates a Buy rating and $75 price target on Silence Therapeutics (SLN) shares following a recent meeting with the company’s management team. At the meeting, management expressed enthusiasm about upcoming catalysts for zerlasiran, a small interfering RNA targeting lipoprotein(a), currently in Phase 2 development for elevated Lp(a), and divesiran, an siRNA targeting TMPRSS6, which is in Phase 2 development for polycythemia vera, the analyst tells investors in a research note. The firm expects collaboration discussions to conclude following the top-line release of results from the Phase 3 cardiovascular outcomes trial, and says a positive outcome from Lp(a) HORIZON could catalyze collaboration opportunities for zerlasiran, which offers several advantages, including less frequent dosing and a favorable efficacy, tolerability, and safety profile.